risperidone has been researched along with Diseases, Metabolic in 13 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with an acute psychotic episode underwent HOMA testing for insulin sensitivity (IS) prior to and after 3 weeks of treatment with olanzapine (n = 7) or risperidone (n = 7)." | 9.16 | The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study. ( Deuschle, M; Kopf, D; Paslakis, G; Rüsse, S; Thome, J, 2012) |
| "Risperidone use in children and adolescents is associated with the development of metabolic disorders including increased accumulation of body fat, dyslipidemia, and glucose and insulin metabolism dysregulation." | 7.96 | Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats. ( Deng, C; Han, M; Sylvester, E; Yi, W, 2020) |
| "Patients with an acute psychotic episode underwent HOMA testing for insulin sensitivity (IS) prior to and after 3 weeks of treatment with olanzapine (n = 7) or risperidone (n = 7)." | 5.16 | The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study. ( Deuschle, M; Kopf, D; Paslakis, G; Rüsse, S; Thome, J, 2012) |
| "Risperidone use in children and adolescents is associated with the development of metabolic disorders including increased accumulation of body fat, dyslipidemia, and glucose and insulin metabolism dysregulation." | 3.96 | Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats. ( Deng, C; Han, M; Sylvester, E; Yi, W, 2020) |
| " Additional prospective studies with accurate dosage information are needed to validate our findings." | 1.62 | Occurrence of metabolic diseases associated with antipsychotic use among Korean patients with schizophrenia. ( Kim, BH; Kim, E; Kim, S; Kuk, S; Lee, W; Park, SI, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Lange, JH | 1 |
| Reinders, JH | 1 |
| Tolboom, JT | 1 |
| Glennon, JC | 1 |
| Coolen, HK | 1 |
| Kruse, CG | 1 |
| Sylvester, E | 1 |
| Yi, W | 1 |
| Han, M | 1 |
| Deng, C | 1 |
| Kuk, S | 1 |
| Kim, S | 1 |
| Kim, E | 1 |
| Kim, BH | 1 |
| Lee, W | 1 |
| Park, SI | 1 |
| Boyda, HN | 1 |
| Procyshyn, RM | 1 |
| Tse, L | 1 |
| Yuen, JWY | 1 |
| Honer, WG | 1 |
| Barr, AM | 1 |
| Matera, E | 1 |
| Margari, L | 1 |
| Palmieri, VO | 1 |
| Zagaria, G | 1 |
| Palumbi, R | 1 |
| Margari, F | 1 |
| Fjukstad, KK | 1 |
| Engum, A | 1 |
| Lydersen, S | 1 |
| Dieset, I | 1 |
| Steen, NE | 1 |
| Andreassen, OA | 1 |
| Spigset, O | 1 |
| Skonieczna-Żydecka, K | 1 |
| Łoniewski, I | 1 |
| Misera, A | 1 |
| Stachowska, E | 1 |
| Maciejewska, D | 1 |
| Marlicz, W | 1 |
| Galling, B | 1 |
| Pérez-Iglesias, R | 1 |
| Martínez-García, O | 2 |
| Pardo-Garcia, G | 1 |
| Amado, JA | 1 |
| Garcia-Unzueta, MT | 1 |
| Tabares-Seisdedos, R | 1 |
| Crespo-Facorro, B | 2 |
| Morlán-Coarasa, MJ | 1 |
| Arias-Loste, MT | 1 |
| Ortiz-García de la Foz, V | 1 |
| Alonso-Martín, C | 1 |
| Crespo, J | 1 |
| Romero-Gómez, M | 1 |
| Fábrega, E | 1 |
| De Hert, M | 1 |
| Mittoux, A | 1 |
| He, Y | 1 |
| Peuskens, J | 1 |
| Paslakis, G | 1 |
| Deuschle, M | 1 |
| Thome, J | 1 |
| Rüsse, S | 1 |
| Kopf, D | 1 |
| Erickson, CA | 1 |
| Stigler, KA | 1 |
| Posey, DJ | 1 |
| McDougle, CJ | 1 |
| Griffiths, J | 1 |
| Springuel, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study[NCT00856583] | Phase 3 | 9,809 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 31 |
| Risperidone | 12 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon the Medical Dictionary for Regulatory Activities (MedDRA) terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 17 |
| Risperidone | 8 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 14 |
| Risperidone | 21 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 13 |
| Risperidone | 21 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 19 |
| Risperidone | 28 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 34 |
| Risperidone | 32 |
The analysis was based on time from start of study drug until stop of study drug for any reason other than sponsor closure of the study (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 3136 |
| Risperidone | 2597 |
The analysis was based on time from start of study drug to first hospitalisation during the WRT+30 days period (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 174 |
| Risperidone | 149 |
"The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 68 |
| Risperidone | 76 |
The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 43 |
| Risperidone | 65 |
Second primary endpoint: a serious adverse event where the patient was hospitalised and for which the Independent Safety Committee (ISC) classified the event as a cardiac event with documented arrhythmia. The analysis of this outcome was not performed due to low number of events. The presented analysis is a replacement analysis using all cardiac events, including arrhythmias, that required hospitalisation (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 10 |
| Risperidone | 6 |
The analysis was based on all deaths from the Whole Randomised Treatment (WRT)+30 days period and the Only Randomised Treatment (ORT) period, respectively (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) | |
|---|---|---|
| Number of deaths (WRT+30 days) | Number of deaths (ORT) | |
| Risperidone | 61 | 44 |
| Sertindole | 64 | 40 |
3 reviews available for risperidone and Diseases, Metabolic
| Article | Year |
|---|---|
Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Gastrointestinal Microbiome; Humans; Hyperglycemia; | 2019 |
Risperidone in pervasive developmental disorders.
Topics: Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Diabetes Mellitus; Expert Testi | 2005 |
Atypical antipsychotics: impaired glucose metabolism.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Glucose; | 2001 |
4 trials available for risperidone and Diseases, Metabolic
| Article | Year |
|---|---|
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Metabolic Disea | 2014 |
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Incidence; Male; Metabolic Diseases; Midd | 2016 |
Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Blood Glucose; Blood Pressure; Body Mass Index; Chi-Square Distri | 2011 |
The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Homeostasis | 2012 |
6 other studies available for risperidone and Diseases, Metabolic
| Article | Year |
|---|---|
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac | 2007 |
Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Body Mass Index; Dyslipidemias; Female; Glucose Tolera | 2020 |
Occurrence of metabolic diseases associated with antipsychotic use among Korean patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Metabolic Diseases; Olanzapine; Prospective Studies; | 2021 |
A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models.
Topics: Animals; Antipsychotic Agents; Female; Glucose Clamp Technique; Glucose Tolerance Test; Insulin Resi | 2021 |
Risperidone and Cardiometabolic Risk in Children and Adolescents: Clinical and Instrumental Issues.
Topics: Adolescent; Antipsychotic Agents; Cardiovascular Diseases; Child; Child, Preschool; Female; Follow-U | 2017 |
Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional S | 2018 |